Next Article in Journal
Why "American Patients First" Is Likely to Raise Drug Prices outside of the United States
Previous Article in Journal
Comparison of Health Technology Assessment for New Medicines in France and England: An Example Based on Ixazomib for Patients with Relapsed or Refractory Multiple Myeloma
 
 
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Systematic Review of Utility Values Used in the Pharmacoeconomic Evaluations for Schizophrenia: Implications on Cost-Effectiveness Results

1
Public Health Department, Aix-Marseille University, Marseille, France
2
Health Economic and Outcome Research Department, Creativ-Ceutical, Paris, France
3
Health Economic and Outcome Research Department, Creativ-Ceutical, Rotterdam, The Netherlands
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2019, 7(1), 1648973; https://doi.org/10.1080/20016689.2019.1648973
Submission received: 24 May 2019 / Revised: 18 July 2019 / Accepted: 22 July 2019 / Published: 22 August 2019

Abstract

Background and Objectives: Utility elicitation studies for schizophrenia generate different utility values for the same health states. We reviewed utility values used in schizophrenia pharmacoeconomic evaluations and evaluated the impact of their selection on the incremental cost-effectiveness ratio (ICER). Methods: A systematic search was performed in Medline and Embase. Health state definitions, associated utility values, elicitation studies, and value selection processes were extracted. Sets of utility values for all schizophrenia health states were used in a cost-effectiveness model to evaluate the ICER. Results: Thirty-five cost-utility analyses (CUAs) referring to 11 utility elicitation studies were included. The most frequent health states were ‘stable’ (28 CUAs, 7 utility elicitation studies, 10 values, value range 0.650–0.919), ‘relapse requiring hospitalisation’ (18, 5, 7, 0.270–0.604), ‘relapse not requiring hospitalisation’ (18, 5, 10, 0.460–0.762), and ‘relapse only’ (10, 5, 6, 0.498–0.700). Seventeen sets of utility values were identified with difference in utility values between relapse and stable ranging from −0.358 to −0.050, resulting in ICERs ranging from −56.2% to +222.6% from average. Conclusion: The use of utility values for schizophrenia health states differs among CUAs and impacts on the ICER. More rigorous and transparent use of utility values and sensitivity analysis with different sets of utility values are suggested for future CUAs.
Keywords: utility; schizophrenia; antipsychotics; pharmacoeconomics; economic model utility; schizophrenia; antipsychotics; pharmacoeconomics; economic model

Share and Cite

MDPI and ACS Style

Zhou, J.; Millier, A.; François, C.; Aballéa, S.; Toumi, M. Systematic Review of Utility Values Used in the Pharmacoeconomic Evaluations for Schizophrenia: Implications on Cost-Effectiveness Results. J. Mark. Access Health Policy 2019, 7, 1648973. https://doi.org/10.1080/20016689.2019.1648973

AMA Style

Zhou J, Millier A, François C, Aballéa S, Toumi M. Systematic Review of Utility Values Used in the Pharmacoeconomic Evaluations for Schizophrenia: Implications on Cost-Effectiveness Results. Journal of Market Access & Health Policy. 2019; 7(1):1648973. https://doi.org/10.1080/20016689.2019.1648973

Chicago/Turabian Style

Zhou, Junwen, Aurélie Millier, Clément François, Samuel Aballéa, and Mondher Toumi. 2019. "Systematic Review of Utility Values Used in the Pharmacoeconomic Evaluations for Schizophrenia: Implications on Cost-Effectiveness Results" Journal of Market Access & Health Policy 7, no. 1: 1648973. https://doi.org/10.1080/20016689.2019.1648973

Article Metrics

Back to TopTop